Pharma Leadership Roundup: Sarepta Therapeutics CEO Announces Retirement, Rivus Pharmaceuticals Appoints New CEO

Key Takeaways

• Sarepta CEO Ingram to step down by end 2026
• Elevidys linked to two deaths, FDA shipment halt
• Sarepta shares down 82% in 2025, 4% today
• Rivus names Jorge Bartolome, former Janssen Canada head
• Rivus targets MASH, obesity with oral GLP‑1 candidates

Pulse Analysis

The biotech industry is witnessing a wave of executive turnover that often foreshadows strategic pivots. Investors closely monitor such changes because leadership stability directly influences pipeline funding, partnership negotiations, and market valuation. Sarepta’s announcement arrives at a time when the company’s credibility has been tested by regulatory scrutiny and a dramatic share price plunge, prompting analysts to reassess its long‑term viability and potential for a turnaround under new stewardship.

Sarepta’s challenges stem largely from the Elevidys episode, where adverse events triggered a voluntary FDA halt and heightened post‑marketing surveillance. The therapy’s sales slump contributed to an 82% decline in 2025, prompting a 500‑person workforce reduction and the suspension of several limb‑girdle muscular dystrophy programs. While the firm is exploring a pathway to expand Elevidys to non‑ambulatory patients, restoring confidence will require robust safety data, transparent communication, and a clear succession plan to reassure shareholders and partners.

Rivus Pharmaceuticals, by contrast, is leveraging fresh leadership to capitalize on the burgeoning market for oral treatments addressing metabolic disease. Jorge Bartolome brings over 25 years of senior pharma experience, including tenure at Janssen and GSK, positioning him to navigate late‑stage development and commercialization hurdles. With Phase II data for HU6 in MASH and an upcoming trial for the GLP‑1‑based RV‑8451 obesity candidate, Rivus aims to capture a sizable share of a market projected to exceed $200 billion. The CEO transition underscores the company’s intent to accelerate pipeline execution and attract strategic partnerships or capital infusions.